SOX方案与FOLFOX4方案一线治疗老年晚期结直肠癌的疗效对比  

Effective comparison of SOX and FOLFOX4 in the first-line therapy of elderly patients with advanced colorectal cancer

作　　者：陈晓梅[1] 晏军[1] 陈世洪[1] 王越希 

机构地区：[1]自贡市第一人民医院肿瘤科,四川自贡643000

出　　处：《现代肿瘤医学》2017年第21期3476-3479,共4页Journal of Modern Oncology

摘　　要：目的:比较奥沙利铂联合替吉奥(SOX方案)与FOLFOX4方案一线治疗老年晚期结直肠癌的有效性和安全性。方法:将86例老年晚期结直肠癌患者分为两组:43例采用SOX方案为观察组,43例采用FOLFOX4方案为对照组。每例患者至少完成2个周期化疗后评价疗效及毒性。结果:观察组与对照组的有效率(RR)分别为51.2%和48.8%,疾病控制率(DCR)分别为81.4%和76.7%,两组比较差异无统计学意义(P>0.05);两组患者的1年生存率分别为53.49%和48.83%,中位肿瘤进展时间(TTP)分别为8.4个月和8.1个月,差异均无统计学意义(P>0.05)。观察组的白细胞减少、恶心呕吐发生率均低于对照组,差异有统计学意义(P<0.05)。结论:SOX与FOLFOX4方案一线治疗老年晚期结直肠癌疗效相似,但SOX方案的耐受性较FOLFOX4方案更好。Objective：To compare the efficacy and safety of oxaliplatin combined with S - 1 （SOX）and FOLFOX4 in the first - line therapy of elderly patients with advanced colorectal cancer. Methods ： Eighty - six elderly patients with advanced colorectal cancer were divided into observation group and control group, observation group adopted SOX regimen,while control group was treated with FOLFOX4 regimen. Patients in both groups received at least 2 cycles of chemotherapy and evaluated the efficacy and toxicity were evaluted. Results：In SOX and FOLFOX4 group, the re- sponse rates（RR） were 51.2% and 48.8% , and the disease control rates（DCR） were 81.4% and 76.7% , which were no significant differences between the two groups（P 〉0.05）. In SOX and FOLFOX4 group,the one- year sur- vival rate were 53.49% and 48.83% ,and the median time to progression（TFP） were 8.4 months and 8.1 months, which were no significant differences between the two groups （ P 〉 0.05 ）. The incidence of nausea and vomiting and white blood cell reduction of the SOX group were significantly lower than that of the FOLFOX4 group, and were signif- icant differences （ P 〈 0.05 ）. Conclusion： SOX has similar efficacy with FOLFOX4, but SOX has better tolerability for the elderly advanced eolorectal cancer.

关 键 词：奥沙利铂 替吉奥 5-氟尿嘧啶 老年患者 晚期结直肠癌 化学治疗 

分 类 号：R735.3[医药卫生—肿瘤]